SSGJ-601 versus Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion: 52-Week Results from a Phase 3 Study

Post time Half hour(s) ago

journal：Ophthalmology Retina

Authors：Linni Wang; Zhiqing Li; Xinjun Ren; Liangzhang Tan; Shuo Zhao; Yingyi Lu; Jilong Hao; Miaoqin Wu; Xinyan Xu; Huijun Shi; Qian Ren; Zhipeng You; Yanping Song; Wenfang Zhang; Chunling Lei; Ximei Zhang; Xian Wang; Wei Tan; Songtao Yuan; Liming Tao; Changzheng Chen; Zongming Song; Wenjuan Zhuang; Hong Zhang; Quanhong Han; Yu Jin; Jianjun Peng; Qing Zhang; Jianlu Gao; Xuemei Pan; Ye Shen; Mingxin Li; Jianfeng Wang; Liangbao An; Xiaoling Liu; Jun Li; Lixun Chen; Hong Wang; Jinglin Zhang; Zixia Zhou; Jingxiang Zhong; Yanling Wang; Tonghe Zhang; Wei Xiong; Ling Cui; Xiaoyan Peng; Mochi Yang; Ming Zhang; Zhuo Li; Hailin Wang; Jing Lou; Yanli Liu; Hong Dai; Xiaorong Li

Published date：2026-8-

DOI：10.1016/j.oret.2026.08.025

PDF link：https://www.sciencedirect.com/sc ... 468653026004318/pdf

Article link：https://doi.org/10.1016/j.oret.2026.08.025

Article Source：Elsevier BV。

Remark：

[Elsevier] SSGJ-601 versus Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion: 52-Week Results from a Phase 3 Study

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] SSGJ-601 versus Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion: 52-Week Results from a Phase 3 Study Copy

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] SSGJ-601 versus Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion: 52-Week Results from a Phase 3 Study